| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PPP1R1B; DARPP32; Protein phosphatase 1 regulatory subunit 1B; DARPP-32; Dopamine- and cAMP-regulated neuronal phosphoprotein |
| Entrez GeneID | 84152 |
| WB Predicted band size | Calculated MW: 23 kDa; Observed MW: 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DARPP32 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DARPP-32抗体的3篇参考文献及其摘要概括：
1. **"Dopamine- and cAMP-regulated phosphoprotein (DARPP-32): A key mediator of dopamine signaling in striatal neurons"**
- **作者**: Greengard, P., et al.
- **摘要**: 该研究首次鉴定了DARPP-32作为多巴胺D1受体下游的关键磷酸化蛋白，并开发了特异性抗体用于检测其在纹状体神经元中的表达及磷酸化状态，揭示了其在多巴胺信号转导中的核心作用。
2. **"DARPP-32 phosphorylation at threonine 34 mediates antipsychotic drug effects via PP-1 inhibition"**
- **作者**: Nishi, A., et al.
- **摘要**: 通过特异性抗体分析，研究发现DARPP-32的Thr34位点磷酸化在抗精神病药物作用机制中至关重要，其通过抑制蛋白磷酸酶PP-1调节下游信号通路，抗体验证了该位点的动态修饰与行为学变化的相关性。
3. **"Altered DARPP-32 expression in schizophrenia post-mortem brains: Evidence from immunohistochemical analysis"**
- **作者**: Karayiorgou, M., et al.
- **摘要**: 利用DARPP-32抗体对精神分裂症患者尸检脑组织进行免疫组化分析，发现纹状体区域DARPP-32蛋白表达显著降低，提示其表达异常可能与疾病病理机制相关。
每篇文献均涉及DARPP-32抗体的具体应用(如Western blot、免疫组化或磷酸化位点分析)，并关联其在神经信号或疾病中的功能。
The DARPP-32 (Dopamine and cAMP-regulated phosphoprotein, 32 kDa) antibody is a critical tool in neuroscience research for studying dopaminergic signaling pathways. DARPP-32. encoded by the *PPP1R1B* gene, is a phosphoprotein highly enriched in medium spiny neurons of the striatum, nucleus accumbens, and cortical regions. It acts as a bidirectional regulator of protein phosphatase-1 (PP1) and protein kinase A (PKA), modulating cellular responses to dopamine, glutamate, and other neurotransmitters. Phosphorylation at specific residues (e.g., Thr34 by PKA or Ser97 by CK2) switches its function, influencing downstream targets linked to synaptic plasticity, reward mechanisms, and motor control.
DARPP-32 is implicated in neuropsychiatric disorders, including schizophrenia, addiction, and Parkinson’s disease, making its study vital for understanding disease mechanisms. Antibodies against DARPP-32 are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to map its expression, localization, and post-translational modifications. These antibodies typically target epitopes in the N-terminal or C-terminal regions, with validation in knockout models ensuring specificity.
First characterized in the 1980s, DARPP-32’s role as a signaling integrator continues to evolve, supported by studies linking its dysregulation to behavioral phenotypes. Research utilizing DARPP-32 antibodies has clarified its involvement in antipsychotic drug effects and psychostimulant-induced plasticity, cementing its status as a biomarker for striatal function.
×
